-

Phase 3 Study of DFP-10917 in the R/R AML Patients Shall Be Done with the 1st Interim Analysis for NDA Approval.

TOKUSHIMA, Japan--(BUSINESS WIRE)--150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2nd, 3rd, or 4th salvage of AML and the 1st interim analysis of this study shall be done for NDA approval to the FDA in US soon after confirmation of the superiority of DFP-10917 arm. The endpoint is CR rate for primary and the Overall Survival for secondary. DFP-10917 (Radgocitabine) was granted as Orphan Drug Designation (ODD) by the FDA in US.

Contacts

Inquiries:
Yasuo Matsueda
Vice President for Business Development
Delta-Fly Pharma, Inc.
Head office: Tokushima 771-0116, Japan
Phone: +81-(0)3-6231-1278
E-mail: ymatsueda1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/

Industry:

Delta-Fly Pharma, Inc.

Release Summary
Delta-Fly Pharma, Inc. completed the patients’ enrollment for the Phase 3 study of DFP-10917 and will start the 1st interim analysis for NDA approval.
Release Versions
EnglishSpanish (Summary)GermanFrenchItalian (Summary)Dutch (Summary)

Contacts

Inquiries:
Yasuo Matsueda
Vice President for Business Development
Delta-Fly Pharma, Inc.
Head office: Tokushima 771-0116, Japan
Phone: +81-(0)3-6231-1278
E-mail: ymatsueda1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/

More News From Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Dec. 9th. in 2024, we are excited to share our latest development status. Regarding the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) in second-line therapy (NCT06382168), the Data Management Committee (DMC) has approved the tolerability of all six patients in the Phase I (dose finding) portion of the Phase I/II study, and we are moving to the P...

Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax

TOKUSHIMA, Japan--(BUSINESS WIRE)--Following to the previous information on Oct. 28th. in 2024, we are excited to share our latest development status. We are pleased to announce that the data review committee (DMC) has approved the tolerability of the first three patients enrolled in the Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) (NCT06382168) conducted at five US clinical sites for patients with acute myeloid leukemia (AML) who have failed/relapsed after standa...

Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729

TOKUSHIMA, Japan--(BUSINESS WIRE)--We are excited to share our latest development status. We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved. In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed aga...
Back to Newsroom